SUBSCRIBE
SUBSCRIBE

Ellen Camacho

Business
Life Sciences Funding Remains Strong as 2021 Winds Down
Life sciences investors are being anything but shy as the end of 2021 draws near. Here are a few companies that are still seeing cash come in the door as December gets underway.
December 6, 2021
 · 
2 min read
 · 
Ellen Camacho
Deals
AcelRx to Buy Lowell Therapeutics; Kala Expands Pipeline with Combangio Acquisition
AcelRx Pharmaceuticals and Kala Pharmaceuticals both shared acquisition news on Monday. Here’s a closer look at each of the acquisition announcements.
November 16, 2021
 · 
2 min read
 · 
Ellen Camacho
Business
New Company Enters AI Space with $40 Million in Hand
DeepCure announced the closing of its $40 million Series A financing round. The round, led by Morningside Ventures, brings the company’s total amount raised to $47 million since it was founded in 2018.
November 9, 2021
 · 
2 min read
 · 
Ellen Camacho
Deals
10 of the Hottest Life Sciences SPAC Merger Announcements So Far This Year
Many mergers took place in 2021. Here’s a look at some of the hottest life sciences SPAC merger announcements so far in 2021. Many mergers took place in 2021,
November 8, 2021
 · 
5 min read
 · 
Ellen Camacho
Job Trends
Life Sciences Industry Sees Burst of Job and Facility Expansions in October
The life sciences industry continues to be one of the fastest growing industries in the world as the end of the year draws near.
October 28, 2021
 · 
3 min read
 · 
Ellen Camacho
Pavlo Gonchar/SOPA Images/LightRocket via Getty Im
Business
10x Genomics Expands Global Reach with New Singapore Facility
10X Genomics is continuing to increase its presence outside of the United States, this time with its first manufacturing facility outside of the country.
October 26, 2021
 · 
2 min read
 · 
Ellen Camacho
Business
Sio Shares Whirlwind of Updates, Including an FDA Fast Track Designation
Sio Gene Therapies had a few big announcements last week, including a Fast Track Designation from the U.S. Food and Drug Administration and the reorganization of its R&D group.
October 25, 2021
 · 
2 min read
 · 
Ellen Camacho
Business
Crinetics Pharma Spinout Launches with Sight Set on Radiopharmaceuticals
Crinetics Pharmaceuticals, along with 5AM Ventures and Frazier Healthcare Partners, announced that it was spinning out a new company, Radionetics Oncology.
October 19, 2021
 · 
2 min read
 · 
Ellen Camacho
Business
Esperion to Cut 40% of Staff as Cholesterol Drugs Fail to Thrive
Products getting regulatory approval and hitting the market doesn’t always spell success for companies, especially during a global pandemic. Michigan-based Esperion has learned that lesson all too well.
October 18, 2021
 · 
2 min read
 · 
Ellen Camacho
Business
New Biotech Company Emerges to Tackle Multifunctional Biotherapeutics
On Thursday, Tentarix Biotherapeutics announced that it earned $50 million in a Series A financing round, which was co-led by Versant Ventures and Samsara BioCapital.
October 15, 2021
 · 
2 min read
 · 
Ellen Camacho
Deals
Life Sciences IPO Scene Buzzing So Far in October
It’s only the second week of October, and the biopharma IPO scene has already been buzzing this month.
October 13, 2021
 · 
2 min read
 · 
Ellen Camacho
ricochet64/Shutterstock
Business
GSK Continues to Switch Up Scenery in Advance of Upcoming Demerger
The scenery will continue to change for GlaxoSmithKline as the company’s planned demerger looms on the horizon. On Monday, GSK gave a glimpse of where the companies will call home post-split.
October 11, 2021
 · 
2 min read
 · 
Ellen Camacho
UBS Hands Over $650 Million to Life Sciences Impact Investment Fund
Funding in the life sciences has been running rampant so far this year, with billions of dollars being funneled to companies from investors.
October 7, 2021
 · 
2 min read
 · 
Ellen Camacho
Genetown
Exo Rakes In $78 Million Series B for Enzyme Inhibitors
Novartis-backed Exo Therapeutics closed out 2020 by completing a $25 million Series A financing round. Nearly 10 months later, the small molecule drug discovery and development company has earned more support from investors.
October 5, 2021
 · 
1 min read
 · 
Ellen Camacho
Business
Xencor and Janssen Unite Again in Second Bispecific Antibodies Agreement
The deal has a value of over one billion dollars, with highlights for Xencor including receiving a $100 million upfront payment, a $25 million equity investment, eligibility for plamotamab royalties and potential milestone payments worth up to $1.18 billion.
October 4, 2021
 · 
2 min read
 · 
Ellen Camacho